Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4485891 | 0.90 | MAPK1 (0.35) | NPC1DGAT1 | |
| SCHEMBL4497857 | 0.83 | FNTA (0.34) | NPC1DGAT1 | |
| SCHEMBL3890080 | 0.81 | DGAT1 (0.32) | NPC1DGAT1 | |
| SCHEMBL3887829 | 0.76 | ADRB2 (0.30) | — | |
| SCHEMBL3883916 | 0.74 | CACNA1H (0.32) | — | |
| SCHEMBL4692865 | 0.73 | NPC1 (0.34) | NPC1 | |
| SCHEMBL6352983 | 0.73 | — | — | |
| SCHEMBL4502812 | 0.72 | NPC1 (0.33) | NPC1DGAT1 | |
| SCHEMBL3883932 | 0.72 | MAPK1 (0.36) | NPC1DGAT1 | |
| SCHEMBL29396507 | 0.70 | NPC1 (0.42) | NPC1DGAT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7550498-B2 | 1,2-Diaza-dibenzoazulenes as inhibitors of tumour necrosis factor production and intermediates for the preparation thereof | GLAXOSMITHKLINE ISTRAZIVACKI CENTAR ZAGREB D.O.O. (HR) | 2009-06-23 | — | — | US | disclosed |
| EP-1587807-B1 | 1,2-DIAZA-DIBENZOAZULENES AS INHIBITORS OF TUMOUR NECROSIS FACTOR PRODUCTION AND INTERMEDIATES FOR THE PREPARATION THEREOF | GLAXOSMITHKLINE ZAGREB (HR) | 2008-06-18 | — | — | EP | disclosed |
| US-20050209296-A1 | 1,2-Diaza-dibenzoazulenes as inhibitors of tumour necrosis factor production and intermediates for the preparation thereof | PLIVA-ISTRAZIVACKI INSTITUT D.O.O. (HR) | 2005-09-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050209296-A1 | 1,2-Diaza-dibenzoazulenes as inhibitors of tumour necrosis factor production and intermediates for the preparation thereof | TNF, IL1A, IL1B | NPC1 2851/4885DGAT1 168/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.